vida: extract claims from 2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound

- Source: inbox/queue/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures.md

@@ -24,3 +24,10 @@ A 2-person AI-staffed GLP-1 telehealth startup reached $1.8 billion in sales run
 **Source:** National Geographic 2025
 
 BMI 16 anorexia patient acquired GLP-1 online by lying about weight. Most patients receive NO eating disorder evaluation before prescription. Psychologist Robyn Pashby: clinicians must 'hold two truths' — efficacy for some, harm risk for others — but screening infrastructure absent.
+
+
+## Extending Evidence
+
+**Source:** NBC News 2024-08-15
+
+NBC News notes 'greater telehealth vs. traditional oversight risk' for ED development in GLP-1 prescribing, suggesting remote prescribing may lack the clinical assessment needed to detect subclinical ED risk factors or monitor for emerging restriction patterns.

domains/health/glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Clinicians disagree on whether EDs develop in properly-prescribed GLP-1 patients, with divergence driven by screening practices and patient population differences rather than resolved evidence
+confidence: experimental
+source: NBC News 2024, contrasting expert opinions from Dr. Aaron Keshen and Dr. Anjali Pandit
+created: 2026-05-05
+title: Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
+agent: vida
+sourced_from: health/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound.md
+scope: structural
+sourcer: NBC News
+supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
+---
+
+# Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
+
+Dr. Aaron Keshen reports EDs developing 'in people who take drugs as prescribed' supporting direct causality, while Dr. Anjali Pandit states 'not seeing this frequently' suggesting prescriber screening matters significantly. This is not a scientific debate about interpretation of shared data — it's a pre-data debate where different clinical populations and practices produce different observed patterns. Keshen's observation supports pharmacological causation; Pandit's suggests population selection (careful screening prevents cases). The divergence itself is evidence of the current state: we are in the clinical pattern recognition phase before systematic epidemiological data. NBC News notes 'no drug label warnings about ED risk currently exist' and the Collaborative of Eating Disorders Organizations is 'calling for mandatory screening before prescribing' — regulatory and professional responses to uncertainty rather than established risk. This represents the characteristic evidence gap where case reports accumulate but incidence rates, risk factors, and causal pathways remain unquantified.

domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-dis
 scope: causal
 sourcer: Clinical Nutrition / VigiBase WHO
 supports: ["glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
-related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal"]
 ---
 
 # GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population
@@ -38,3 +38,10 @@ Methodological discrepancy between studies reveals sensitivity of signal detecti
 **Source:** PMC DAEN analysis, Australia 2025
 
 Australian DAEN database shows exceptionally high ROR (17.66) for dulaglutide eating disorder reports compared to US/Canadian databases, suggesting either: (1) small denominator effects in lower-volume database, (2) population-specific differences in drug response or reporting patterns, or (3) higher clinical awareness/reporting rates in Australian healthcare system. This geographic heterogeneity in signal strength warrants investigation of population-level moderators.
+
+
+## Extending Evidence
+
+**Source:** NBC News 2024-08-15
+
+FDA adverse event analysis found 'greater risk of abuse among patients taking semaglutide' compared to other weight-loss drugs (not quantified). Psychologist Tom Hildebrandt reports increase in ED patients taking GLP-1s over 6-month observation window. Journal of Clinical Psychopharmacology published case of patient abusing medication, losing 50 lbs in 9 months. All evidence remains case-report or clinical observation level as of August 2024.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: causal
 sourcer: MDPI Nutrients
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
 ---
 
 # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
@@ -24,3 +24,10 @@ This review establishes that GLP-1 receptor agonists create opposing clinical ou
 **Source:** PMC/Journal of Clinical Medicine systematic review, 2025
 
 2025 case documented: woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. This provides clinical case evidence for the restrictive ED harm pathway, showing that even medically supervised GLP-1 use can trigger relapse in patients with prior restrictive ED history.
+
+
+## Supporting Evidence
+
+**Source:** NBC News 2024-08-15
+
+Clinicians describe progression from beneficial appetite suppression to pathological restriction, with 'atypical anorexia nervosa' pattern emerging. Cynthia Landrau case shows restrictive eating pattern (consuming one-third recommended calories) developing after initial appetite suppression benefit.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -31,3 +31,10 @@ Study explicitly acknowledges indication bias limitation: 'The databases used in
 **Source:** ANAD 2026 clinical guidance
 
 ANAD's epistemic honesty is striking: 'We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors.' The national professional society acknowledges insufficient evidence to make clear recommendations, yet the medications are being prescribed at scale without screening infrastructure. The gap is not knowledge availability but operational implementation.
+
+
+## Supporting Evidence
+
+**Source:** NBC News 2024-08-15
+
+Collaborative of Eating Disorders Organizations calling for mandatory screening before prescribing, indicating current practice lacks standardized pre-treatment ED assessment. No drug label warnings about ED risk exist as of August 2024 despite accumulating case reports.

domains/health/glp1-starvation-spiral-hypothesis-caloric-deficit-triggers-obsessive-restriction.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Brain interprets dramatic GLP-1-induced weight loss as starvation, activating obsessive food thoughts and restriction behaviors independent of pre-existing ED vulnerability
+confidence: speculative
+source: NBC News 2024, expert commentary from clinicians observing case patterns
+created: 2026-05-05
+title: GLP-1-mediated caloric deficit may trigger starvation-response restriction through neurobiological misinterpretation of pharmacological appetite suppression as famine
+agent: vida
+sourced_from: health/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound.md
+scope: causal
+sourcer: NBC News
+supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway"]
+---
+
+# GLP-1-mediated caloric deficit may trigger starvation-response restriction through neurobiological misinterpretation of pharmacological appetite suppression as famine
+
+Multiple clinicians quoted in NBC News describe a progression pattern: beneficial appetite suppression → pathological restriction → 'atypical anorexia nervosa' presentation. The proposed mechanism is that the brain 'may interpret dramatic sudden weight loss as starvation, triggering obsessive food thoughts' — a neurobiological feedback loop where pharmacological caloric reduction activates evolutionary starvation-response circuits that then reinforce restriction behavior. The Cynthia Landrau case exemplifies this: 28-year-old consuming 'only about one-third of calories recommended for a woman her age' with 'no mentioned prior ED history' (though absence of evidence is not evidence of absence). This differs from the population-selection hypothesis (GLP-1s prescribed to people with subclinical ED risk) by proposing a direct pharmacological → neurological → behavioral pathway. Critical limitation: 'no mentioned prior history' ≠ 'confirmed no prior history' — the NBC reporter did not probe for subclinical body image concerns or dietary restriction patterns. All evidence is case-report level with no systematic data on incidence rates or risk factors.

inbox/archive/health/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound.md

@@ -7,10 +7,13 @@ date: 2024-08-15
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, eating-disorders, semaglutide, wegovy, anorexia, causality, case-report, anhedonia]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content